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Abstract
For more than a decade, the cytokine interleukin-12 (IL-12) has been utilized, either alone or in combination with other
drugs, as a treatment for cancer. The numerous anti-tumor properties of IL-12 still generate interest in the clinical use of this
cytokine, even though it has demonstrated toxicity when administrated systemically. As an approach to overcome this
toxicity, numerous laboratories have attempted to induce IL-12 expression at the site of the tumor. However for tumors that
are difficult to remove surgically or for the treatment of disseminated metastases, systemic expression of this cytokine still
remains as the most efficient method of administration. Nevertheless, finding alternative approaches for the use of IL-12 in
the treatment of cancer and unraveling the basis of IL-12-side effects remain a challenge. In the present work we
demonstrate that systemic expression of IL-12 through hydrodynamic injection of IL-12 cDNA is able to induce different
types of liver lesions associated with a toxic pathology. However we report here that hepatic toxicity is diminished and
survival of mice enhanced in the absence of tumor necrosis factor alpha (TNFa). This observation is in contrast to several
murine models and clinical trials that postulate interferon gamma (IFNc) as the main cytokine responsible for IL-12 toxicity.
Moreover, our work demonstrates that when IL-12 cDNA is co-injected with IL-18 cDNA or when mice are pre-treated with a
low dose of IL-12 cDNA prior to receiving a high dose of IL-12 cDNA, systemic levels of TNFa are almost completely
abrogated, resulting in improved survival and less hepatic damage. Importantly, abrogation of TNFa signaling does not
affect the strong anti-tumor activity of IL-12. Thus, neutralizing TNFa with antagonists already approved for human use
offers a promising approach to abrogate IL-12 side effects during the use of this cytokine for the treatment of cancer.
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Introduction
The immunomodulating and anti-angiogenic functions of IL-12
have provided the rationale for exploiting this cytokine as an
anticancer agent. More than a decade ago, clinical trials
administering IL-12 for the treatment of tumors, including T cell
lymphoma [1], non-Hodgkin lymphoma [2], melanoma [3],
ovarian cancer [4], Kaposi’s sarcoma [5], and renal carcinoma
[6] were initiated. Systemic IL-12 was shown to be capable of
suppressing tumor growth, metastasis, and angiogenesis in vivo [7–
11], but its use has been associated with significant dose- and
schedule-dependent toxicity, representing a major obstacle to its
clinical application [1,3,4,6,7]. Grade 1-4 toxicity, has inhibited
the use of IL-12 as a cancer therapy. However, alternative
approaches for the use of IL-12 are under intensive investigation in
animal models of cancer and in recent clinical trials [12–16].
Several clinical trials utilizing IL-12 have demonstrated that
increased levels of the inflammatory cytokine IFNc were
associated with different grades of hepatotoxicity and other toxic
side effects [2,4,6,17]. Moreover, in several murine models, the
IFNc expression induced after IL-12 administration was found to
be responsible for most of the observed adverse effects [18–21].
Utilizing different murine tumor models, we have previously
reported that systemic levels of IL-12 alone or together with IL-18,
induced after hydrodynamic injection of the respective cDNAs,
completely abrogated subcutaneous tumor growth and pulmonary
and hepatic metastases [10]. Moreover, co-expression of IL-
12+IL-18 was able to improve survival by diminishing IL-12-side
effects [10]. Our previous work also demonstrated that IFNc was
partially responsible for the IL-12-side effects. Moreover, our data
demonstrated that increased survival of IL-12+IL-18-treated mice
is associated with early IL-10 production and a reduction of IFNc
and TNFa serum levels [10]. In this context, the present work
demonstrates that by using hydrodynamic injection to induce
systemic co-expression of IL-12+IL-18 cDNAs or by pre-injecting
a low dose of IL-12 cDNA prior to a large dose of IL-12 cDNA, we
observed significantly increased survival and diminished hepato-
toxicity. Interestingly, both methods demonstrate that this effect is
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highly associated with abrogation of TNFa expression, an
inflammatory cytokine that also plays a pathological role in sepsis
shock and in vivo LPS treatment [22–25]. Together, the data
presented in this work contributes to our understanding of the
basis for IL-12-systemic side effects. Furthermore, we propose that
depending upon the system used to induce systemic IL-12
expression; different toxic mediators could be the protagonists of
adverse side effects. Moreover, data presented in this manuscript
can serve as the basis for the development of new approaches to
decrease IL-12 toxicity when designing future therapies for cancer
treatment involving this cytokine.
Materials and Methods
Mice and cell lines
C57BL/6 (B6) mice, 6-10 weeks of age, were used and
maintained under specific pathogen-free conditions. Inducible
nitric oxide synthase (iNOS) knock out (KO), TNFa KO and
TNFa receptor one (TNFaR1) KO mice on a C57BL/6 genetic
background were purchased from the Jackson Laboratories, Bar
Harbor, ME, USA. Animal care was provided in accordance with
the procedures outlined in the Guide for the Care and Use of
Laboratory Animals (NIH-Publication No. 86–23, 1985). The
experimental protocols were approved by the Institutional Animal
Care and Use Committee of Centro de Investigaciones en
Bioquı´mica Clı´nica e Inmunologı´a (CIBICI), Consejo Nacional
de Investigaciones Cientı´ficas y Te´cnicas (CONICET). Our
animal facility has obtained NIH animal welfare assurance
(assurance no. A5802-01, Office of Laboratory Animal Welfare,
NIH, Bethesda, MD, USA). In order to avoid animal suffering,
mice were rapidly sacrificed by cervical dislocation. During
intrasplenic (i.s.) tumor cell injection, a shorter time of surgery
was applied and the incisions were made as minimal as possible
during the procedure. During recovery from surgery, mice were
placed in warm blankets and their eyes were hydrated with a saline
solution. Animals were placed back in cages after total recovery
from the surgery.
B16-F10 melanoma cells were obtained from American Type
Culture Collection. The cell line was free of Mycoplasma infection
and tested by PCR every 6 months. B16-F10 melanoma cells were
cultured in DMEM containing 10% FBS, 100 U/ml penicillin,
100 mg/ml streptomycin, and nonessential amino acids at 37uC,
5% CO2.
Hydrodynamic cDNA injections
The hydrodynamic gene transfer procedure has been described
previously [10,26]. Briefly, animals were injected in the tail vein in
less than 8 seconds with the respective cDNAs dissolved in 1.6 ml
of sterile 0.9% sodium chloride solution and divided into 3 groups,
control: 5–15 mg of ORF empty vector control cDNA, IL-12: 5 mg
of IL-12 cDNA (pscIL-12, p40-p35 fusion gene) and IL-12+IL-18:
5 mg of IL-12 cDNA (pscIL-12, p40-p35 fusion gene) plus 10 mg of
IL-18 cDNA (pDEF pro-IL-18). All the expression plasmids utilize
the human elongation 1-a promoter to drive transcription.
The in vivo effects observed upon cytokine induction are purely
due to the expression of the cytokine cDNAs and not by LPS
contamination. WT and TLR4 KO mice develop similar levels
and kinetics of TNFa expression after IL-12 cDNA treatment thus
indicating the absence of LPS in the cytokine cDNA preparation
used for injection (data not shown).
Spleen samples
For cytokines analysis of in vitro stimulated cells, spleens were
smashed, depleted of red cells by incubation in ACK lysing buffer
(Biowhittaker, Walkersville, MD), washed and resuspended in
supplemented media (RPMI 1640, 10% FBS, 2 mM L-glutamine,
561025 M 2-mercaptoethanol, 1 mM sodium pyruvate and
nonessential amino acids). Cell suspensions were counted and
stimulated in vitro with supplemented media, anti-CD3 coated
antibody (Ab) (BD-Pharmingen, La Jolla, CA) at 2 mg/ml or LPS
(Sigma-Aldrich, St. Louis, MO) at 1 mg/ml for 72 h in an
incubator set at 37uC and 5% CO2.
Cytokine and ALT assays
Sera were assayed for cytokine production by ELISA according
to the manufacturers’ instructions. The kits utilized were: mIL-10,
mIFNc, mTNFa (BD-Pharmingen, La Jolla, CA). Alanine
aminotransferase (ALT) sera levels were determined using a
specific colorimetric kit (Wiener Laboratories) and by following the
manufacturer’s instructions.
Hystopathological analysis of hepatic tissue
Livers obtained from mice in the different treatment groups
were harvested on day 15 post cDNA treatment, fixed in 4%
formaldehyde and then embedded in paraffin. 6 mm sections were
prepared and hematoxilin/eosin (H/E) or Periodic acid-Schiff
(PAS) stains were applied to the sections. Sections, without
identification, were analyzed for tissue alterations under an optical
microscope by a pathologist.
Flow cytometry analysis
For multicolor staining, fluorocrome-conjugated Abs (BD-
Pharmingen, La Jolla, CA) against lineage markers were used in
various combinations. Briefly, Fc receptors on cells were blocked
with an anti-CD16/32 Ab for 30 min at 4uC and washed. Cells
were then stained for surface markers for 30 min at 4uC, washed
twice and analyzed by flow cytometry with a BD FACS CantoTM
II cytometer (BD Biosciences, San Jose´, CA, USA). For flow
cytometry cell sorting, splenocytes from IL-12+IL-18-cDNA
treated mice were stained with fluorocrome-labeled CD4 (clone
RM4-5), CD8 (clone 53-6.7), CD11b (clone M1/70) and CD11c
(clone HL3) antibodies (BD-Pharmingen, La Jolla, CA) and sorted
to a purity of 97–99% using a MoFlo sorter (Dako Cytomation).
mRNA extraction and analysis
Total RNA was isolated using a single-step phenol/chloroform
extraction procedure (TrIzol; Invitrogen Life Technologies). RT-
PCR was performed with 100 ng of total RNA for each sample
(Super Script III one step RT-PCR with platinum Taq,
Invitrogen), consisting of a 15 minute reverse transcription
reaction at 45uC, 40 cycles of denaturing at 94uC (15 s), annealing
at 55uC (30 s) and extension at 68uC (60 s), with a final extension
for 5 min at 68uC. Primers used were: iNOS, sense 59-GCA TTT
GGG AAT GGA GAC TG-39, antisense 59-GTT GCA TTG
GAA GTG AAG CGT TTC-39.
Western immunoblotting
Splenocytes were lysed with 150 ml ice-cold lysis buffer and
centrifuged at 14,000 rpm, 4uC for 5 min. Proteins extracts were
electrophoresed on a 10% SDS-PAGE gel and transferred onto an
Immun-Blot PVDF Membrane (BIO-RAD, Hercules, CA).
Membranes were blocked with 5% milk, 0.1% Tween-20 in
TBS overnight at 4uC and then were incubated with primary
antibodies for 3 h at room temperature. After incubation with a
horseradish-peroxidase conjugated secondary antibody (Cell Sig-
naling Technology, Inc. Beverly, MA), the protein bands were
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detected with a Super Signal Chemiluminescent Substrate (Pierce)
and BIOMAX-MR film (Eastman Kodak, Rochester, NY).
Arginase Activity Assay
Triton X-100 (0.1%, 100 ml) was added to the splenocyte pellets
that were then treated as indicated. After 30 min incubation, Tris-
HCl and MnCl2 mixture (100 ml) were added to cells for 10 min at
56uC. The plates were incubated with L-arginine (100 ml) at 37uC
for 30 min, and then an H2SO4/H3PO4/H2O mixture (800 ml)
was added and heated with a-isopropylidene nitrobenzene acetone
(50 ml) at 95uC for 30 min. The complex in each well was diluted
20 times with PBS to detect the optical density (OD) values at
540 nm with a UV spectrophotometer.
Hepatic metastasis assay and subcutaneous tumor
growth
C57BL/6 and TNFaRI KO mice were i.s. injected with B16-
F10 melanoma cells (0.56106 cells/0.5 ml 0.9% sodium chloride
solution) for hepatic metastasis analysis. Three days later, cDNAs
were delivered by hydrodynamic injection. Eleven days later, livers
were collected and the number of metastases was determined
under a dissecting microscope.
To evaluate subcutaneous tumor growth, C57BL/6 and
TNFaRI KO mice were shaved and injected s.c. in the left flank
with 16106 B16-F10 melanoma cells in 0.2 ml of a sterile 0.9%
sodium chloride solution. After 10–14 days, when solid tumors
were visible (4–5 mm diameter), mice were hydrodynamically
injected with the designated cDNAs. Tumor growth was
Figure 1. Relative absolute cell numbers of splenic cell subpopulations in mice hydrodynamically injected with cytokine cDNAs.
C57BL/6 mice were hydrodynamically injected with control, IL-12 and/or IL-18 cDNAs. Up to 50 days post-injection, animals were sacrificed and single
cells suspensions of splenic cells were obtained. The percentage of the different subsets was obtained by surface lineage staining with combination
of the following Abs: NK1.1, CD3, CD11b, CD19, CD4 and CD8 and analyzed by flow cytometry. Relative cell numbers of the different cell populations
were calculated by dividing the absolute cell numbers obtained from the cytokine-treated mice by the absolute cell numbers obtained from control
mice. Data is expressed as the mean of a pool of 4 different experiments (total n = 12 mice per group). *12+18 and 12 vs control p,0.05, #12 vs
12+18 p,0.05.
doi:10.1371/journal.pone.0090116.g001
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monitored with a caliper. Day 0 corresponds to the day when
cDNAs were administrated.
Statistical analysis
For statistical significance, data was analyzed by means of a
Student unpaired t test (comparison of 2 experimental groups) or
ANOVA test (composition of more than 2 experimental groups)
with p,0.05 considered as significant. Non-parametric test
(Kruskal-Wallis test) was utilized when n was less than 10. Mouse
survival curves were plotted as Kaplan – Meier plots using
GraphPad Prism Version 4 (GraphPad Software, San Diego, CA)
and a p,0.05 was considered as significant.
Results
Changes in leucocytes numbers after systemic
expression of IL-12 or IL-12+IL18
We have previously demonstrated that depletion of T cells and
NK/NKT cells increases survival of IL-12-treated mice [10].
However, a residual toxicity persists after T/NK/NKT cell
depletion, suggesting that other cell types could also be part of the
IL-12-adverse effects [10]. As a first step to investigating this issue
we analyzed the relative changes in the numbers of leucocytes
present in the spleen (and liver, not shown) compared to control
mice. As seen in Figure 1, the numbers of NK and NKT subsets
are highly reduced up to 50 days post-treatment following
administration of either IL-12 or IL-12+IL-18 cDNAs. This data
seemed quite surprising since depletion of NK/NKT cells
correlates with improvement in survival of mice treated with IL-
12 cDNA. However, when we evaluated the phenotype of NK
cells obtained from IL-12-treated mice, we observed that they
express high levels of IFNc and the early activation marker CD69
(data not shown). This data suggests that even though they are
found in very low numbers, NK/NKT cells demonstrate an
activated phenotype and thus may be partially responsible for the
toxicity observed after systemic expression of IL-12.
We also observed an alteration in the number of T lymphocytes
following cytokine cDNA administration. While CD4+ T cells
show a lower cellularity during most time periods analyzed, CD8+
T cells undergo an expansion in numbers during the first week
after treatment but then subsequently return to normal levels
(fig.1).
Next we evaluated the macrophage (Mw) population in the
treated mice. IL-12 alone induces an early increase in Mw
numbers while in contrast, the number of these cells in IL-12+IL-
18-treated mice is not expanded (days 2 and 3 post-treatment).
Moreover, even though Mw numbers reach a higher peak in IL-
12+IL-18 treated mice by day 10, they return to normal levels by
day 50 post-treatment while the number of Mw in the IL-12
treated group is still elevated. The fact that a pathogenic role for
these cells in another murine model of IL-12+IL-18 systemic
expression has been previously reported [19], we hypothesize that
mediators produced by Mw could be responsible, at least in part,
for the toxic side effects observed after systemic IL-12 treatment.
The balance between nitric oxide (NO) expression and
arginase activity suggests a more inflammatory profile in
macrophages from IL-12-treated compared to IL-12+IL-
18-treated mice
Next, we investigated the role of NO as a basis for IL-12-side
effects as NO is known to be induced by Mw in the presence of IL-
12+IL-18 [27]. The generation of NO by neutrophils and
monocytes is increased in septic patients and their persistence is
associated with a poor clinical outcome [28]. Moreover, excessive
NO formation plays an important role in the pathogenesis of shock
Figure 2. inflammatory profile of Mw following IL-12 cDNA treatment. (A) RT-PCR analysis of iNOS gene expression in splenocytes obtained
from mice injected with the designated cDNAs, 12+18 and 12 vs control p,0.05. (B) Western blot analysis of splenocyte protein extracts obtained
from mice injected with the designated cDNAs, 12 vs 12+18, p,0.05. (C) Survival monitored in B6 (WT) or iNOS KO mice in the days post-IL-12 or IL-
12+IL-18-cDNA injection. (D) Arginase activity measured determination of urea levels in 16106 splenocytes. The data in A, B and D are expressed as
the mean of 2 different experiments with 4–5 mice per group. Survival curve was built as a pool of 2 different experiments with 5 mice per group.
*12+18 vs 12 p,0.05.
doi:10.1371/journal.pone.0090116.g002
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and multiple organ failure during sepsis and in acute lung injury
[29]. In this context, we first analyzed if NO/iNOS is expressed in
our experimental model. As can be seen in Figure 2A, iNOS RNA
expression is significantly up-regulated in both IL-12 and IL-
12+18-treated mice early after cDNA administration and persists
for at least 15 days after treatment (data not shown). Interestingly,
protein analysis revealed that after 15 days post-treatment, iNOS
expression is still up-regulated in IL-12-treated mice but lower or
no expression is observed in IL-12+IL-18-treated mice (Fig. 2B).
Moreover, in vitro NO levels evaluated on day 15 post treatment
from splenocytes stimulated with LPS showed a lower expression
in cells obtained from IL-12+IL-18-treated mice (data not shown).
These data led us to determine if the lower expression of iNOS/
NO in IL-12+IL-18-treated mice could explain the improved
survival outcome observed in this group, as compared to IL-12-
treated mice [10]. Surprisingly, when we monitored survival in
WT and iNOS KO mice after IL-12 or IL-12+IL-18 cDNA
administration, we observed that the lack of iNOS expression does
not improve resistance to the treatments (Fig. 2C). These results
led us to hypothesis that NO might not be directly involved as a
toxic mediator of these treatments but the relation between Mw
NO/arginase expression could be providing information about the
inflammatory environment resulting from the different treatments.
Accordingly, figure 2D shows that splenocytes from IL-12-treated
mice have significantly lower arginase activity when compared to
splenocytes from IL-12+IL-18-treated mice. Together with the
iNOS data, we conclude that the NO/arginase ratio is higher in
mice treated with IL-12 alone than in mice treated with IL-12+IL-
18. This result suggests that the treatment with IL-12+IL-18
induced a macrophage phenotype less inflammatory when
compared to IL-12 treated mice.
Expression of IFNc, TNFa and IL-10 after IL-12+IL-18
treatment
We have reported that in IL-12+IL-18-treated mice, early
expression of IL-10 controls the levels of the inflammatory
cytokines IFNc and TNFa [10]. However, even though we
performed these experiments by depleting different leucocytes
populations and evaluating survival in each case, we could not
identify the sources of the cytokines [10]. To investigate this issue,
we evaluated the production of IL-10, IFNc and TNFa from
sorted splenocytes obtained from IL-12+IL-18-treated mice on day
3 post treatment, a timepoint at which we had previously observed
production of these cytokines (Figure 3). We observed that TNFa
is highly produced by CD8+ T cells and CD11b+ plus CD11c+
cells (Mw, dendritic cells (DCs) and natural killer (NK) cells sorted
together). Since NK cells and DCs represent a very small
population of splenocytes in these mice (Fig. 1 and data not
shown), we sorted all these cells together to increase the number of
recovered cells. To determine the contribution of Mw alone, we
evaluated the cytokine expression in cultures of enriched adherent
splenocytes (.85% Mw) and observed that these cells also
expressed high levels of TNFa. This observation suggested that
the expression of TNFa may come mainly from Mw rather than
the other 2 cell types present in the CD11b/c+ sorted group
(Fig. 3A). In contrast, IFNc is expressed by CD4+ and CD8+ T
cells but not from Mw, demonstrating that CD11b/c expression is
probably due to the presence of NK cells in this group (Fig. 3B).
Interestingly, IL-10 is produced by CD4+ T cells and also by DCs
or NK cells but not by Mw (Fig. 3C). This data suggests that
depletion of T, NK and NKT cells, could eliminate the sources of
IFNc (as we previously reported [10]), but Mw still remain as a
very important source of TNFa. This finding is probably why
depletion of the lymphocytes only partially improved survival in
IL-12-treated mice [10]. Moreover, the fact that the Mw profile
seems to be more inflammatory based on the NO/arginase data,
could explain why IL-12-treated mice exhibit much lower survival
than IL-12+IL-18-treated mice.
TNFa is an important cytokine that mediates IL-12
systemic toxicity
To investigate the role of TNFa as a toxic mediator after IL-12
systemic expression, we analyzed survival of TNFa KO or
TNFaR1 KO mice after IL-12 treatment. As seen in Figure 4A,
Figure 3. Splenocytes produce Th1 and Th2 cytokines after IL-
12+IL-18 cDNA treatment. Splenocytes from IL-12+IL-18 mice were
obtained and stained with anti-CD4, anti-CD8 and anti-CD11b/c
fluorocrome labeled Abs and then sorted to a purity of 97–99% using
a MoFlo sorter (Dako Cytomation). Sorted cells were then cultured in
the presence of anti-CD3 coated Ab (2 mg/ml) and LPS (1 mg/ml) for
72 h. Supernatants were then harvested and (A) TNFa, (B) IFNc and (C)
IL-10 expression were evaluated by ELISA. Data are expressed as the
mean of 2 different experiments with 4-5 mice per group. *Stimulated
vs non-stimulated, p,0.001.
doi:10.1371/journal.pone.0090116.g003
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abrogation of TNFa or its type 1 receptor genes significantly
increased survival of IL-12-treated mice compared to WT mice.
Interestingly, when we analyzed the kinetics of TNFa serum levels,
we observed that protein expression peaks around day 4 both in
IL-12+IL-18- and in IL-12-treated mice; however, the levels are
much lower in IL-12+IL-18-treated mice (Fig. 6C). Moreover, by
day 8 and up to day 12 post-treatment, TNFa sera levels begin to
decline in both groups; however, it remains persistent and always
higher in the IL-12 treatment group (Fig. 4B).
Next, we compared TNFa in vitro expression by splenocytes
obtained from the mice treated in vivo with IL-12 alone or with IL-
12+IL-18. While TNFa produced after in vitro stimulation with an
anti-CD3 Ab (stimulation of T cells) is quite similar between cells
obtained from both groups, it is significantly lower in IL-12+IL-18-
treated mice when stimulated in vitro with LPS (i.e. Mw and DCs
stimulation) (Fig. 4C). This data suggests that the lower levels of
systemic TNFa observed in IL-12+IL-18-treated mice is probably
due to a reduced contribution of Mw and DCs in the expression of
this cytokine in this treatment group.
Systemic IL-12 or IL-12+IL-18 treatment provokes
pathological effects in immune tissues and the liver
Systemic expression of IL-12 has been reported to induce
several types of pathological changes in mouse models and in
cancer patients [2,4,6,17]. To evaluate the general toxicity of IL-
12 treatment, we sacrificed control and sick IL-12 and IL-12+IL-
18 treated mice and performed a complete analysis of organ
pathology. As can be seen in Table S1, the major alterations
observed are atrophy of the thymus and lymphoid depletion, and
these changes appeared similar in IL-12 and IL-12+IL-18 treated
mice.
However, the analysis also revealed a more intense histiocytosis
in lymph nodes (LNs) obtained from IL-12-treated mice compared
to IL-12+IL-18-treated mice. Histiocytosis is associated with the
presence of macrophages in the tissue, so the exacerbated
pathology in IL-12 treated mice is associated with a major
expansion/presence of macrophage in LNs.
Alterations in hepatic tissue after systemic expression of
IL-12 or IL-12+IL-18
Even though we did not observe differences in histiocytosis
when comparing the livers of IL-12 and IL-12+IL-18 mice,
previous results confirmed that sera levels of the hepatic enzymes
ALT and aspartate aminotransferase (AST) were significantly
higher in IL-12-treated mice [10]. Next we decided to evaluate the
pathology of this organ in lieu of the finding that one of the most
undesirable effects of systemic IL-12 therapy is the hepatotoxicity
observed after the administration of this cytokine [2,4,6,17].
Interestingly, as shown in Figure 4D, IL-12 treatment of TNFa
type 1 receptor KO mice abrogates the ALT peak observed by day
15 in WT mice.
The histopathological features present in the livers of mice
treated with IL-12 or IL-12+IL-18 cDNAs revealed major changes
in the tissue, including the appearance of: cells with a round shape
Figure 4. TNFa plays a critical role in mediating IL-12 systemic adverse effects. (A) Survival was monitored in WT, TNFa KO and TNFRI KO
mice in the days post-IL-12 cDNA treatment. *WT vs TNFa KO and TNFRI KO, p,0.01. (B) Mice from control, IL-12 or IL-12+IL-18-cDNA treated groups
were bled and TNFa sera levels were determined in the days post-treatment. (C) Splenocytes from control, IL-12 or IL-12+IL-18 cDNA treated mice
were obtained and cultured in the presence of media (NS), anti-CD3 coated Ab or LPS for 72 h. Supernatants were then harvested and TNFa
expression was evaluated by ELISA. *IL-12 vs IL-12+IL-18, p,0.05. (D) Sera from B6 mice treated with control or IL-12 cDNA and from TNFRI KO mice
treated with IL-12 cDNA were obtained in the days post-treatment. ALT levels were determined using a specific colorimetric kit. The data in A, B and C
are expressed as the mean of 2 different experiments with 4 mice per group. The data in D are expressed as the mean of the pool of 3 different
experiments (WT n= 12, TNFR1 KO n= 9). *WT IL-12 cDNA vs TNFRI KO IL-12 cDNA, p,0.05.
doi:10.1371/journal.pone.0090116.g004
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(cell ballooning) (Fig. 5B) compared to the classical hexagonal
shape of hepatocytes from control mice (Fig. 5A). Moreover, the
livers from treated mice show the loss of the hepatic sinusoids that
can be clearly observed in control mice (Figs. 5A vs 5B).
Additionally, we observed foci of ectopic hematopoiesis (Fig. 5C)
with the presence of megakaryocytes (Fig. 5D) throughout the liver
in IL-12- or IL-12+IL-18-treated mice but not in control mice.
Both Mallory bodies (Fig. 5E) and Councilman bodies (Fig. 5F)
and foci of necrotic tissue (Fig. 5G) can only be seen in mice
treated with the cytokine cDNAs. Finally, we observed that
glycogen deposits are highly reduced in mice treated with IL-12 or
IL-12+IL-18 (Fig. 5I) compared to control mice (Fig. 5H). Even
though all these lesions are present throughout the liver tissue in
mice treated with either IL-12 cDNA alone or IL-12+IL-18
cDNAs (peaking between days 14–16), co-administration of IL-12
and IL-18 is able to reduce the incidence of these IL-12-associated
hepatic abnormalities (Table S2). These observations correlate
with our previous data that demonstrated lower ALT and AST
sera levels in 12+IL-18-treated mice [10]. Moreover, TNFaR1
KO mice (Fig. 5K) exhibited a lower incidence of these
pathological features after IL-12 cDNA treatment than what was
observed in treated WT mice (Fig. 5J), especially in the number
and size of infiltrate foci (Table S2).
Correlation of TNFa adverse effects with clinical data in
cancer patients treated with IL-12
Clinical trials results with IL-12 protein administration and in
murine models demonstrated that a low dose of IL-12 given prior
to a larger dose of IL-12 (dose escalating protocols) prevents major
toxicity by the high dose IL-12 [17,30–32]. Therefore the question
arises as to whether pre-dosing with a low dose of IL-12 in our
model might have the same effect as co-administration of IL-18
cDNA, and if so, might the treatment regime also work via early
IL-10 induction and attenuation of TNFa and IFNc levels.
To test this hypothesis, we pre-injected mice with a low dose of
IL-12 cDNA followed 2 days later by a high dose of IL-12 cDNA.
We evaluated serum expression of IL-10, TNFa and IFNc in this
group and compared the data with mice injected with IL-12
cDNA alone or IL-12+IL-18 cDNA. As we previously reported
[10], a significant increase in survival can be observed in IL-
12+IL-18 cDNA-treated mice compared to mice treated with IL-
12 cDNA alone (Fig. 6A). Interestingly, when mice were pre-
Figure 5. Histopathological alterations in hepatic tissue after systemic expression of IL-12 or IL-12+IL-18. Livers obtained from mice in
the different groups were obtained on day 14-16 post-cDNA treatment. Sections of 6 mm were obtained and (A–G) hematoxilin/eosin (H/E) or (H–I)
Periodic acid-Schiff (PAS) stains were applied to the sections. (A) Hepatocytes and sinusoids from a control mouse, 1006. (B) Ballooning hepatocytes
and absence of hepatic sinusoids in an IL-12-cDNA treated mouse, 1006. (C) Focus of ectopic hematopoiesis in an IL-12-cDNA treated mouse, 1006.
(D) Megakaryocyte in an IL-12-cDNA treated mouse, 1006. (E) Mallory and (F) Councilman bodies in an IL-12-cDNA treated mouse, 1006. (G) Focus of
necrosis; 106. Glycogen deposits obtained in a mouse from (H) the control group or (I) the IL-12-cDNA group, 206. Liver sections from (J) WT or (K)
TNFR1 KO mice 15 days after IL-12 cDNA treatment. Pictures are representative of 2 different experiments with 4–5 mice per group.
doi:10.1371/journal.pone.0090116.g005
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injected with a low dose of IL-12 cDNA, a significant increase in
survival is detected similar to what is observed in IL-12+IL-18-
cDNA treated mice. These data encouraged us to investigate if
pre-dosing with IL-12 is able to trigger a similar protective
mechanism as observed when co-injecting with IL-12+IL-18
cDNA. We analyzed cytokine sera levels in all groups of mice
up-to 7 days post-treatment and interestingly, IFNc and IL-10
serum levels expression is up-regulated early after treatment only
in IL-12+IL-18 cDNA treated mice but not in the rest of the
groups (Fig. 6B). Furthermore, mice that demonstrate a better
survival (IL-12+IL-18 and pre-low dose IL-12 cDNA groups) are
also in the groups that show very low levels of TNFa in the sera. In
contrast, elevated sera TNFa correlates with a poor outcome in
IL-12 cDNA-treated mice (Fig. 6A and 6C). It is important to
clarify that IL-12 serum levels induced after the different
treatments are similar (data not shown), thus the differences in
TNFa levels cannot be attributed to differences in IL-12
expression following hydrodynamic injection.
Blocking TNFa signaling ameliorates IL-12-side effects
without affecting the IL-12 antitumor capacity
The data we have presented demonstrates a pathological role
for TNFa after systemic expression of IL-12. Moreover, we have
proven that incorporating alternatives to IL-12 systemic admin-
istration (IL-12+IL-18 and pre-low dose IL-12 cDNA) highly
ameliorates IL-12-side effects by reducing TNFa sera levels. In
order to prove that the blockage of TNFa signaling could be
considered for cancer patients treated with IL-12, we must
demonstrate that abrogation of TNFa does not affect the powerful
antitumor capacity of IL-12. In order to test this hypothesis, we
evaluated the antitumor effect of IL-12 in WT and TNFR1 KO
mice utilizing the B16 melanoma subcutaneous tumor and liver
metastases murine models. Similar to our previous report [10], we
found that administration of IL-12 cDNA almost completely
abrogates the growth of B16 s.c. tumors either in WT or TNFR1
KO mice (upper panel of Figure 7). Moreover, after IL-12
treatment, both strains of mice show lower hepatomegaly and a
reduction in the size and number of B16 hepatic metastases
(Figure 7, lower panel).
As a whole, the data presented in this work demonstrate an
important role of TNFa in the toxicity mediated by systemic
expression of IL-12. We can conclude that different treatment
protocols that lead to a control of TNFa levels (e.g. treatment with
anti-TNF antibodies or with soluble TNF receptor) warrant
consideration when designing new cancer therapies utilizing IL-
12, without risking its potent antitumor activity.
Discussion
Eradication of residual malignancies and metastatic tumors via
a systemic approach is the key for successfully treating cancer and
Figure 6. IL-12+IL-18 co-expression and low amounts of IL-12 cDNA reduce IL-12-side effects by decreasing TNFa expression. B6
mice were treated with IL-12 cDNA alone (black circle), IL-12+IL-18 cDNA (open circle) or low IL-12 cDNA (0,5 mg) 2 days prior to administration of a
high amount of IL-12 cDNA (5 mg) (black square). (A) Survival was monitored and (B) IFNc, (C) TNFa and (C) IL-10 sera expression were evaluated by
ELISA in the days post-treatment. The data are expressed as the mean of 2 different experiments with 5 mice per group. IL-12+IL-18 or IL-12 low cDNA
+ IL-12 high cDNA vs IL-12, ***p,0.01 or #p,0.05. IL-12+IL-18 vs the rest of the groups, *p,0.05.
doi:10.1371/journal.pone.0090116.g006
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increasing cancer patient survival. Several clinical trials in patients
with different type of cancers have demonstrated that systemic
administration of IL-12 protein in a large acute dose is effective in
only a percentage of the patients but toxic in most of patients [1–
6]. However, the strong anti-angiogenic properties of IL-12,
together with its capacity to mount a powerful T cell immune
response against the tumor are still being exploited in recent
clinical trials [12,13]. Moreover, in order to diminish IL-12
toxicity, several laboratories have attempted to deliver IL-12 to the
site of the tumor, with promising results [1,33,34]. However, in the
case of metastases or tumors difficult to access, systemic IL-12
administration still represents the best treatment option. Thus, the
development of alternatives to IL-12 systemic use and identifying
the molecules responsible for its side effects will contribute to
expanding the use of IL-12 in the treatment of cancer.
In this context, our previous data showed that co-expression of
IL-12 plus IL-18 cDNA achieved strong anti-tumor effects, similar
to IL-12 cDNA alone, along with a significant increase in survival
[10]. This observation was quite surprising as it has been
previously reported that a synergistic, albeit toxic, effect was
observed when both cytokines were co-administrated as recombi-
nant proteins [19,35]. In order to understand the mechanism of
toxicity in this model and how co-expression of both cytokines
induced benefits in tolerating the treatment, we previously
analyzed IFNc expression as this cytokine was reported to play
an important role in mediating IL-12-side effects [18,19,35].
Consistent with this hypothesis, most experimental models and
clinical trials point to IFNc as the cytokine involved in IL-12-side
effects [7,18,19,35]. However, in the present model of cDNA
administration that results in systemic expression of IL-12+IL-18,
we have previously reported an ambiguous role for IFNc, as its
reduction improved survival but its complete abrogation induced
100% death of mice treated with IL-12 or IL-12+IL-18 (probably
due to pulmonary edema) [18,35]. Taking this data into account,
we focused our attention on identifying other possible toxic
mediators responsible for IL-12 side effects. We present evidence
here that TNFa acts as a critical cytokine that mediates IL-12-
adverse effects. Consistent with our findings, TNFa has been
described as the major mediator in the pathogenesis of other
inflammatory conditions, including septic shock [22–25].
Our previous data demonstrated that simultaneous depletion of
T and NK cells significantly ameliorates survival in mice treated
with IL-12 cDNA [10]. With this data in mind, we speculate that
this effect is due to abrogation of the different sources of TNFa.
Interestingly, data from the present work demonstrates that TNFa
production is observed in T cells, NK cells and also in Mw. This
residual Mw TNFa expression is probably why we observed that a
percentage of mice depleted of NK-T cells still succumb following
IL-12 cDNA treatment [10]. Moreover, we demonstrate here that
when comparing NO vs arginase levels together with TNFa
production, Mw from IL-12+IL-18-treated mice seems to exhibit a
lower inflammatory profile when compared to IL-12-treated mice.
Hepatotoxicity is one of the most undesirable side effects
observed after systemic IL-12 treatment and yet the consequences
of TNFa systemic expression on liver pathology has not been
carefully studied [2,4,6,17]. We report here several hystopatholo-
gical alterations develop in mice treated with IL-12 or IL-12+IL-
18 cDNA and these alterations have been previously associated
with liver toxicity. These effects include Mallory bodies and
hepatocytes ballooning as seen in alcoholic and non alcoholic
hepatitis [36,37] and necrosis and Councilman bodies observed in
Dengue fever and hepatitis C virus infection [38,39]. Moreover,
Figure 7. Abrogation of TNFa signaling does not affect IL-12 antitumor activity. For subcutaneous tumor growth, 16106 B16 cells were
injected s.c. in C57BL/6 (WT) and TNFR1 KO mice (8–10 weeks old). Between days 10–14, when tumors had reached a size of approximately 5 mm,
mice were hydrodynamically injected with IL-12 cDNA. In the days post cDNA injection, tumor growth was measured with a caliper (upper panel). For
liver metastases analysis, intrasplenic injection was performed on day 0 with 0.56106 B16 melanoma cells and 3 days later with IL-12 cDNA via
hydrodynamic shear. Liver examination was performed on day 14 post treatment (lower panel). IL-12 vs control p values are plotted in the figure. The
data in the upper panel are expressed as the mean of 2 different experiments with 4 mice per group. Pictures of the lower panel are representative of
2 different experiments with 4–5 mice per group.
doi:10.1371/journal.pone.0090116.g007
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further evidence of liver damage comes from the fact that we
detected highly increased ALT and AST serum levels in the
cytokine cDNA treated mice [10]. Interestingly, both the liver
enzymes levels and the changes in the liver tissue are reduced in
mice treated with IL-12+IL-18 cDNA compared to mice treated
with IL-12 cDNA alone. Furthermore, we demonstrate here that
abrogation of TNFa or its type 1 receptor reduces ALT levels and
hepatic alterations and also improves survival of IL-12 cDNA
treated mice. Additionally and consistent with our model, TNFa is
almost absent from the serum in IL-12+IL-18 cDNA treated mice.
The data presented in this work points to TNFa more than
IFNc as a major pathological mediator resulting from systemic IL-
12 expression. Somewhat surprisingly, these results are in contrast
to several reports that conclude that IFNc expression after IL-12
or IL-12+IL-18 administration is responsible for IL-12 toxicity
[18,19,35]. Based on data from murine models and clinical trials
[17,30–32], the reduced toxicity observed after pre-treating with a
low dose of IL-12 before administration of a high dose of IL-12 or
treatment with both IL-12 and IL-18 cDNA, may act through the
control of systemic TNFa levels.
Overall, the data presented in this manuscript contribute new
insights into the clinical use of IL-12 by revealing strong evidence
that TNFa may act as the main molecule responsible for IL-12-
side effects. Based on the fact that abrogation of TNFa does not
affect the potent IL-12 antitumor capacity, this work supports the
development of alternatives approaches and therapies capable of
reducing toxicity, including the addition of approved TNFa
antagonists (infliximab, adalimumab, etc), when using IL-12 in
cancer patients.
Supporting Information
Table S1 Pathology in mice treated with systemic IL-12 or
IL-12+IL-18. A complete body examination was performed by a
pathologist in mice treated with control, IL-12 or IL-12+IL18 cDNAs.
Table S1 shows the description only in the organs that present any
pathological alterations.
(PPTX)
Table S2 Hepatic pathology in mice treated with systemic
IL-12 or IL-12+IL-18. Quantitative analysis of the indicated
pathological conditions in B6 or TNFaR1 KO mice treated with
control, IL-12 or IL-12+IL-18 cDNAs. Infiltration = mononuclear
cells and hematopoeisis. Cellular lesions = Cell balloning and Mallory
and Councilman bodies. - = no pathology; + = mild; ++ =
moderate; +++ = marked
(PPTX)
Acknowledgments
We thank Mike Sanford for performing and analyzing the ELISAs data,
Diego Lutti, Fabricio Navarro and Luis Navarro, John Wine and Tim Back
for their support in animal care and experimentation. We also thank Bioq.
Paula Icely for technical assistance and Bioq. Luciano P. Pedrotti for
hydrodynamic injections. We thank Lic. David Nocera for B16 cell
inoculation and Bioq. Emiliano Roselli and Lic. Paula Araya for B16 cell
culture maintenance. We thank Dr. Paula Abadie and Dr. Pilar Crespo for
cell sorting and flow cytometry assistance.
Author Contributions
Conceived and designed the experiments: MCRG. Performed the
experiments: BB NSB DR PI MCRG. Analyzed the data: HC HAY
MCRG. Contributed reagents/materials/analysis tools: PI HC. Wrote the
paper: MCRG.
References
1. Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, et al. (2001) The role for
interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci 941:
177–184. PubMed: 11594571.
2. Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, et al. (2002) Phase 1
study of interleukin-12 in combination with rituximab in patients with B-cell
non-Hodgkin lymphoma. Blood 99: 67–74. doi:10.1182/blood.V99.1.67.
PubMed: 11756154.
3. Hamid O, Solomon JC, Scotland R, Garcia M, Sian S, et al. (2007) Alum with
interleukin-12 augments immunity to a melanoma peptide vaccine: correlation
with time to relapse in patients with resected high-risk disease. Clin Cancer Res
13: 215–222. PubMed: 17200357.
4. Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, et al. (2007) Phase II
study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with
peritoneal carcinomatosis (residual disease , 1 cm) associated with ovarian
cancer or primary peritoneal carcinoma.J Transl Med 5: 66. doi: 10.1186/1479-
5876-5-66. PM:18076766.
5. Yarchoan R, Pluda JM, Wyvill KM, Aleman K, Rodriguez-Chavez IR, et al.
(2007) Treatment of AIDS-related Kaposi’s sarcoma with interleukin-12:
rationale and preliminary evidence of clinical activity. Crit Rev Immunol 27:
401–414. PubMed: 18197804.
6. Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, et al. (1999) Phase I
study of subcutaneously administered recombinant human interleukin 12 in
patients with advanced renal cell cancer. Clin Cancer Res 5: 3983–3989.
PubMed: 10632329.
7. Mazzolini G, Prieto J, Melero I (2003) Gene therapy of cancer with interleukin-
12. Curr Pharm Des 9: 1981–1991. doi: 10.2174/1381612033454261. PubMed:
12871184.
8. Sgadari C, Angiolillo AL, Tosato G (1996) Inhibition of angiogenesis by
interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87:
3877–3882. PubMed: 8611715.
9. Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and
adaptive immunity. Nat Rev Immunol 3: 133–146. PubMed: 12563297.
10. Rodriguez-Galan MC, Reynolds D, Correa SG, Iribarren P, Watanabe M, et al.
(2009) Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity
through a rapid induction of IL-10 without affecting its antitumor capacity.
J Immunol 183: 740–748. doi: 10.4049/jimmunol.0804166. PubMed:
19535628.
11. Coughlin CM, Salhany KE, Wysocka M, Aruga E, Kurzawa H, et al. (1998)
Interleukin-12 and interleukin-18 synergistically induce murine tumor regression
which involves inhibition of angiogenesis. J Clin Invest 101: 1441–1452.
PubMed: 9502787.
12. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, et al. (2008) Phase I trial
of interleukin-12 plasmid electroporation in patients with metastatic melanoma.
J Clin Oncol 26: 5896–5903. doi: 10.1200/JCO.2007.15.6794. PubMed:
19029422.
13. Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, et al.
(2009) A phase I trial of paclitaxel and trastuzumab in combination with
interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer
Ther 8: 2983–2991. doi:10.1158/1535-7163.MCT-09-0820. PubMed:
19887543.
14. Hallaj-Nezhadi S, Lotfipour F, Dass C (2010) Nanoparticle-mediated interleu-
kin-12 cancer gene therapy. J Pharm Pharm Sci 13: 472–485. PubMed:
21092717.
15. Chiang CL, Maier DA, Kandalaft LE, Brennan AL, Lanitis E, et al. (2011)
Optimizing parameters for clinical-scale production of high IL-12 secreting
dendritic cells pulsed with oxidized whole tumor cell lysate. J Transl Med 9: 198.
doi: 10.1186/1479-5876-9-198. PubMed: 22082029.
16. Lopez MV, Adris SK, Bravo AI, Chernajovsky Y, Podhajcer OL (2005) IL-12
and IL-10 expression synergize to induce the immune-mediated eradication of
established colon and mammary tumors and lung metastasis. J Immunol 175:
5885–5894. PubMed: 16237081.
17. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, et al. (1997)
Phase I evaluation of intravenous recombinant human interleukin 12 in patients
with advanced malignancies. Clin Cancer Res 3: 409–417. PubMed: 9815699.
18. Car BD, Eng VM, Schnyder B, LeHir M, Shakhov AN, et al. (1995) Role of
interferon-gamma in interleukin 12-induced pathology in mice. Am J Pathol
147: 1693–1707. PubMed: 7495294
19. Carson WE, Dierksheide JE, Jabbour S, Anghelina M, Bouchard P, et al. (2000)
Coadministration of interleukin-18 and interleukin-12 induces a fatal inflam-
matory response in mice: critical role of natural killer cell interferon-gamma
production and STAT-mediated signal transduction. Blood 96: 1465–1473.
PubMed: 10942393.
20. Lui VW, Falo LD, Jr., Huang L (2001) Systemic production of IL-12 by naked
DNA mediated gene transfer: toxicity and attenuation of transgene expression in
vivo. J Gene Med 3: 384–393. doi: 10.1002/jgm.201. PubMed: 11529668.
TNFa Toxicity during IL-12 Immunotherapy in Cancer
PLOS ONE | www.plosone.org 10 February 2014 | Volume 9 | Issue 2 | e90116
21. Mazzolini G, Narvaiza I, Perez-Diez A, Rodriguez-Calvillo M, Qian C, et al.
(2001) Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer
of interleukin-12. Gene Ther 8: 259–267. PubMed: 11313799.
22. Ito H, Koide N, Hassan F, Islam S, Tumurkhuu G, et al. (2006) Lethal
endotoxic shock using alpha-galactosylceramide sensitization as a new
experimental model of septic shock. Lab Invest 86: 254–261. doi:10.1038/
labinvest.3700388. PubMed: 16446706.
23. Tsuji H, Mukaida N, Harada A, Kaneko S, Matsushita E, et al. (1999)
Alleviation of lipopolysaccharide-induced acute liver injury in Propionibacteri-
um acnes-primed IFN-gamma-deficient mice by a concomitant reduction of
TNF-alpha, IL-12, and IL-18 production. J Immunol 162: 1049–1055. PubMed:
9916732.
24. Mayoral JL, Schweich CJ, Dunn DL (1990) Decreased tumor necrosis factor
production during the initial stages of infection correlates with survival during
murine gram-negative sepsis. Arch Surg 125: 24–27. doi:10.1001/archsurg.
1990.01410130026003. PubMed: 2294880.
25. Miethke T, Wahl C, Heeg K, Echtenacher B, Krammer PH, et al. (1992) T cell-
mediated lethal shock triggered in mice by the superantigen staphylococcal
enterotoxin B: critical role of tumor necrosis factor. J Exp Med 175: 91–98.
PubMed: 1730929.
26. Rodriguez-Galan MC, Bream JH, Farr A, Young HA (2005) Synergistic effect of
IL-2, IL-12, and IL-18 on thymocyte apoptosis and Th1/Th2 cytokine
expression. J Immunol 174: 2796–2804. PubMed: 15728489.
27. Bastos KR, Barboza R, Sardinha L, Russo M, Alvarez JM, et al. (2007) Role of
endogenous IFN-gamma in macrophage programming induced by IL-12 and
IL-18. J Interferon Cytokine Res 27: 399–410. doi:10.1089/jir.2007.0128.
PubMed: 17523872.
28. Santos SS, Brunialti MK, Rigato O, Machado FR, Silva E, et al. (2012)
Generation of nitric oxide and reactive oxygen species by neutrophils and
monocytes from septic patients and association with outcomes. Shock 38: 18–23.
doi: 10.1097/SHK.0b013e318257114e. PubMed: 22575991.
29. Lange M, Enkhbaatar P, Nakano Y, Traber DL (2009) Role of nitric oxide in
shock: the large animal perspective. Front Biosci 14: 1979–1989. doi:10.2741/
3357. PubMed: 19273179.
30. Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, et al. (2000) Phase
I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal
cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is
associated with clinical response. Clin Cancer Res 6: 1678–1692. PubMed:
10815886.
31. Motzer RJ, Rakhit A, Schwartz LH, Olencki T, Malone TM, et al. (1998) Phase
I trial of subcutaneous recombinant human interleukin-12 in patients with
advanced renal cell carcinoma. Clin Cancer Res 4: 1183–1191. PubMed:
9607576.
32. Portielje JE, Lamers CH, Kruit WH, Sparreboom A, Bolhuis RL, et al. (2003)
Repeated administration of interleukin (IL)-12 are associated with persistently
elevated plasma levels of IL-10 and declining IFNc, umor necrosis factor-a, IL-6
and IL-8 responses. Clin Cancer Res 9: 76–83. PubMed: 12538454.
33. Egilmez NK, Kilinc MO, Gu T, Conway TF (2007) Controlled-release
particulate cytokine adjuvants for cancer therapy. Endocr Metab Immune
Disord Drug Targets 7: 266–270. PubMed: 18220947.
34. Rakhmilevich AL, Timmins JG, Janssen K, Pohlmann EL, Sheehy MJ, et al.
(1999) Gene gun-mediated IL-12 gene therapy induces antitumor effects in the
absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J
Immunother 22: 135–144. PubMed: 10093038.
35. Nakamura S, Otani T, Ijiri Y, Motoda R, Kurimoto M, et al. (2000) IFN-
gamma-dependent and -independent mechanisms in adverse effects caused by
concomitant administration of IL-18 and IL-12. J Immunol 164: 3330–3336.
PubMed: 10706727.
36. Taniguchi H, Shibagaki K, Seshimo K, Kobayashi K (2012) A case of alcoholic
hepatitis diagnosed by a liver biopsy and successfully treated by corticosteroid
therapy. Nihon Shokakibyo Gakkai Zasshi 109: 630–637. PubMed: 22481265.
37. Suzuki A, Abdelmalek MF, Schwimmer JB, Lavine JE, Scheimann AO, et al.
(2012) Association between puberty and features of nonalcoholic fatty liver
disease. Clin Gastroenterol Hepatol 10: 786–794. doi: 10.1016/
j.cgh.2012.01.020. PubMed: 22343513.
38. Huerre MR, Lan NT, Marianneau P, Hue NB, Khun H, et al. (2001) Liver
histopathology and biological correlates in five cases of fatal dengue fever in
Vietnamese children. Virchows Arch 438: 107–115. PubMed: 11253111.
39. Errico-Grigioni A, Fiorentino M, Vasuri F, Gruppioni E, Fabbrizio B, et al.
(2008) Tissue hepatitis C virus RNA quantification and protein expression help
identify early hepatitis C virus recurrence after liver transplantation. Liver
Transpl 14: 313–320. doi: 10.1002/lt.21375. PubMed: 18306349.
TNFa Toxicity during IL-12 Immunotherapy in Cancer
PLOS ONE | www.plosone.org 11 February 2014 | Volume 9 | Issue 2 | e90116
